NCT03353675View on ClinicalTrials.gov

A Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With the Therapeutic Vaccine Named TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC)

PHASE2CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

January 5, 2018

Primary Completion Date

November 20, 2019

Study Completion Date

February 17, 2021

Conditions
Non Small Cell Lung Cancer Metastatic
Interventions
BIOLOGICAL

TG4010

1 dose (1x1E+08) Subcutaneous injection/week over 6 weeks then 1 dose/3 weeks

DRUG

Chemotherapy

"Pemetrexed/Cisplatin or Carboplatin~Pemetrexed maintenance"

DRUG

Nivolumab

360 mg IV administration every 3 weeks

Trial Locations (9)

28204

Charlotte, Charlotte

37203

Nashville, Nashville

Unknown

Libramont, Libramont

Créteil, Créteil

Mulhouse, Mulhouse

Rennes, Rennes

Strasbourg, Strasbourg

Budapest, Budapest

Szekesfehervar, Székesfehérvár

Sponsors

Lead Sponsor

Transgene

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Transgene

INDUSTRY

NCT03353675 - A Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With the Therapeutic Vaccine Named TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC) | Biotech Hunter | Biotech Hunter